Article

Companies join forces to market laser in Europe

Topcon Europe Medical BV will distribute and market the LensAR Inc. product line (including a laser) in Europe under the terms of an agreement between the two companies. They expect commercial sales to start on the continent in the first quarter of next year.

Rotterdam, Netherlands, and Orlando-Topcon Europe Medical BV will distribute and market the LensAR Inc. product line (including a laser) in Europe under the terms of an agreement between the two companies. They expect commercial sales to start on the continent in the first quarter of next year.

“This is a very exciting opportunity for Topcon to significantly broaden our activities in ocular surgery,” said Eric Franken, managing director of Topcon Europe Medical BV. “We are well-known for our strengths in ocular diagnostics, and now we intend to use our strong direct sales presence in Europe to market the LensAR laser system to the benefit of our customers and their patients.”

Randy Frey, president and chief executive officer LensAR Inc., said: “We are very pleased to join forces with such a strong strategic partner. Topcon . . . is ideally positioned to market [the] . . . laser system in the European market.”

The laser system is cleared by the FDA for anterior capsulotomy and lens fragmentation. For other indications, it is an investigational device in the United States. To date, the system has been used in more than 500 eyes outside of the United States.

For more articles in this issue of

Ophthalmology Times Conference Brief

click here

.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.